Gsk (GSK) Change in Account Payables (2011 - 2013)

Gsk (GSK) recorded quarterly Change in Account Payables of $69.6 million in Q4 2013, up 194.25% quarter-over-quarter from -$73.9 million in Q4 2012, and up 194.25% on a YoY basis from $23.7 million in Q4 2012.

Gsk (GSK) Change in Account Payables (2011 - 2013) Analysis & Trends

Gsk's Change in Account Payables history runs 3 years deep, the most recent figure standing at $69.6 million for Q4 2013.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Account Payables (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn -
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn -
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn -
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn -
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn -
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn 571.00 Mn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn -67.00 Mn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn -
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn 409.00 Mn
10 Novartis Ag 112.59 Bn 111.90 Bn - -53.00 Mn

Historic Data

Download Data
DateValue
Dec 31, 2013 69.62 Mn
Dec 31, 2013 69.62 Mn
Dec 31, 2012 -73.87 Mn
Dec 31, 2012 -73.87 Mn
Dec 31, 2011 75.44 Mn
Dec 31, 2011 75.44 Mn